Meningoencephalomyelitis of Unknown Origin

Meningoencephalomyelitis of Unknown Origin (MUO) is a collective term used in veterinary neurology to describe a group of non-infectious, presumed immune-mediated inflammatory diseases affecting the central nervous system (CNS) of dogs. These conditions are characterized by inflammation of the meninges, brain parenchyma, and spinal cord, without a detectable infectious etiology. The term encompasses several distinct histopathologic entities, including granulomatous meningoencephalomyelitis (GME), necrotizing meningoencephalitis (NME), necrotizing leukoencephalitis (NLE), and eosinophilic meningoencephalitis (EME). Clinically, MUO presents with a wide spectrum of neurological signs, ranging from focal or multifocal forebrain signs to brainstem and spinal cord deficits. The disease is typically progressive and can be rapidly fatal if untreated. Diagnosis is based on clinical presentation, advanced imaging (MRI), cerebrospinal fluid (CSF) analysis, and exclusion of infectious causes. Treatment relies on immunosuppressive doses of corticosteroids and adjunctive immunomodulatory agents. Prognosis is variable, with some patients achieving long-term remission, while others experience rapid deterioration or relapse.

The exact etiology of MUO remains unknown, but it is widely believed to be immune-mediated. Several hypotheses have been proposed: (1) an aberrant T-cell-mediated immune response directed against CNS antigens, possibly triggered by a molecular mimicry mechanism following an infection or vaccination; (2) a primary autoimmune disorder with genetic predisposition; (3) a viral or other infectious agent that has not yet been identified. No consistent infectious agent has been isolated from affected dogs, and extensive testing for viral, bacterial, fungal, and protozoal pathogens is typically negative. Some studies have suggested a possible association with certain viral infections (e.g., canine distemper virus, but this is not confirmed) or with vaccination, but no causal link has been established. Genetic factors are likely, as certain breeds are overrepresented, such as Pugs, Maltese, Yorkshire Terriers, and Chihuahuas, suggesting a heritable component. The immune response is characterized by perivascular infiltration of mononuclear cells (lymphocytes, macrophages, plasma cells) and, in some forms, eosinophils, leading to inflammation, demyelination, and necrosis of neural tissue.

MUO is primarily a disease of dogs, with rare reports in cats. It accounts for approximately 25% of all inflammatory CNS diseases in dogs. The disease can occur at any age, but it most commonly affects young to middle-aged dogs, with a median age of 4-6 years. There is no strong sex predilection, though some studies suggest a slight female predominance. Certain breeds are significantly overrepresented, including Pugs, Maltese, Yorkshire Terriers, Chihuahuas, French Bulldogs, and Cocker Spaniels. In particular, NME is commonly seen in Pugs and Maltese, while NLE is more frequent in Yorkshire Terriers and French Bulldogs. GME, the most common form, can affect any breed but is often seen in small-breed dogs. The incidence is not well-defined, but it is considered a sporadic disease. No geographic or seasonal patterns have been consistently identified, although some studies have reported a higher incidence in certain regions, possibly due to genetic clustering. The disease is not contagious, and no environmental risk factors have been conclusively identified.

The pathophysiology of MUO involves an immune-mediated inflammatory response within the CNS. The inciting trigger is unknown, but it is hypothesized that a molecular mimicry mechanism, where an infectious agent or vaccine antigen shares epitopes with CNS proteins, leads to activation of autoreactive T-cells. These T-cells cross the blood-brain barrier (BBB) and initiate a delayed-type hypersensitivity reaction. The inflammatory infiltrate is predominantly composed of CD3+ T-lymphocytes and macrophages, with variable numbers of plasma cells and, in eosinophilic forms, eosinophils. The inflammation is typically perivascular, forming cuffs around blood vessels, and can be diffuse or focal. In GME, the characteristic lesion is a granulomatous reaction with accumulation of macrophages and lymphocytes, often forming nodular masses. In NME and NLE, there is severe necrosis of the neuropil and leukoencephalomalacia, respectively, with minimal granuloma formation. The inflammatory process leads to disruption of the BBB, edema, demyelination, neuronal death, and gliosis. These pathological changes result in neurological deficits corresponding to the affected regions of the CNS. The disease can be rapidly progressive, and the inflammatory response can cause significant intracranial hypertension, leading to herniation and death.

Several factors may predispose dogs to MUO. Genetic predisposition is the most significant, as certain breeds have a high incidence, suggesting an inherited susceptibility. For example, Pugs with NME often have a specific haplotype of the dog leukocyte antigen (DLA) class II genes, indicating a genetic basis. Age is a factor, as the disease is more common in young to middle-aged dogs. Sex may play a role, with some studies showing a slight female predilection. Environmental factors, such as stress, concurrent illness, or vaccination, have been proposed as triggers, but evidence is inconclusive. Immunosuppression, either due to disease or medication, may increase susceptibility to the aberrant immune response. Additionally, dogs with a history of recent vaccination (within 2-4 weeks) have been reported to develop MUO, but a causal relationship has not been proven. Other potential predisposing factors include a history of infectious diseases, though no specific agent has been identified.

Clinical signs of MUO are highly variable and depend on the location and extent of inflammation. The onset can be acute or chronic, and the course may be progressive or relapsing. Common signs include seizures (focal or generalized), which are often the presenting sign in forebrain involvement. Other forebrain signs include behavioral changes, circling, head pressing, and visual deficits. Brainstem involvement can lead to cranial nerve deficits (e.g., facial nerve paralysis, vestibular signs), ataxia, and proprioceptive deficits. Spinal cord involvement may cause paresis or paralysis, with or without spinal pain. Meningeal inflammation often results in cervical hyperesthesia (neck pain) and stiffness. Systemic signs such as fever, lethargy, and anorexia may be present but are not consistent. In some cases, the disease presents as a focal mass lesion, mimicking a brain tumor, with signs such as hemiparesis or seizures. The clinical course can be peracute (rapid deterioration within days), acute (within weeks), or chronic (over months). In severe cases, signs of increased intracranial pressure, such as stupor, coma, and abnormal pupillary light reflexes, may occur.

The differential diagnoses for MUO include infectious meningoencephalitis (viral, bacterial, fungal, protozoal, rickettsial), neoplastic conditions (primary brain tumors such as glioma, meningioma, or metastatic tumors), other non-infectious inflammatory diseases (e.g., steroid-responsive meningitis-arteritis), and vascular events (e.g., ischemic stroke or hemorrhage). Specific infectious causes to rule out include canine distemper virus, rabies, West Nile virus, Ehrlichia, Rickettsia, Borrelia, Neospora, Toxoplasma, Cryptococcus, Blastomyces, and Aspergillus. Neoplastic diseases can mimic MUO on MRI, especially when there is a focal mass lesion. Steroid-responsive meningitis-arteritis (SRMA) typically presents with severe neck pain and fever, and CSF analysis shows marked neutrophilic pleocytosis, which is distinct from the mononuclear pattern of MUO. Vascular events often have an acute onset and may show a specific vascular distribution on MRI. Definitive diagnosis requires CSF analysis, advanced imaging, and sometimes brain biopsy. Key differentiating features include CSF cell type (mononuclear vs. neutrophilic), MRI characteristics (e.g., multifocal T2 hyperintensities, contrast enhancement patterns), and response to therapy.

The diagnostic approach to MUO involves a stepwise algorithm: 1) Complete neurological examination to localize the lesion (forebrain, brainstem, cerebellum, spinal cord). 2) Baseline laboratory tests (CBC, serum biochemistry, urinalysis) to rule out systemic disease. 3) Advanced imaging, preferably MRI of the brain and/or spinal cord, which is the most sensitive modality for detecting inflammatory lesions. MRI findings typical of MUO include multifocal T2-weighted hyperintensities in the white matter, gray matter, or meninges, with variable contrast enhancement. In GME, there may be a focal mass lesion with ring enhancement. In NME, there are often asymmetric, poorly demarcated lesions in the cerebral cortex. 4) CSF analysis, which is crucial for diagnosis. CSF is collected from the cisterna magna or lumbar site, ideally after MRI to avoid post-ictal changes. Typical CSF findings in MUO include increased protein concentration and mononuclear pleocytosis (lymphocytes and macrophages), with or without eosinophils. 5) Infectious disease testing, including serology and PCR for common pathogens, to rule out infectious causes. 6) In ambiguous cases, brain biopsy may be considered for definitive histopathologic diagnosis, but it is rarely performed due to the risks. 7) Response to immunosuppressive therapy can also support the diagnosis.

Routine hematology and serum biochemistry are often unremarkable in MUO, but may show mild non-specific changes such as leukocytosis or elevated acute-phase proteins. CSF analysis is the most important laboratory test. Typical findings include increased CSF protein concentration (usually >25 mg/dL, often >50 mg/dL) and pleocytosis, with a predominance of mononuclear cells (lymphocytes and macrophages). In eosinophilic meningoencephalitis, eosinophils may be present. CSF pressure may be elevated. In some cases, CSF may be normal, especially in the early stages or in focal forms. Specific biomarkers, such as CSF antibodies against glial fibrillary acidic protein (GFAP) or myelin basic protein, have been investigated but are not routinely used. PCR testing for infectious agents (e.g., Toxoplasma, Neospora, Cryptococcus, canine distemper virus) on CSF is recommended to rule out infectious causes. Serology for infectious diseases (e.g., Ehrlichia, Rickettsia, Borrelia) may be performed on blood. In cases with suspected systemic inflammation, C-reactive protein (CRP) may be elevated, but it is not specific.

MRI is the imaging modality of choice for MUO. Findings are variable depending on the form. In GME, there may be single or multiple contrast-enhancing lesions, often with a 'ring' or 'nodular' pattern, located in the white matter, brainstem, or cervical spinal cord. In NME, lesions are typically asymmetric, T2-hyperintense, and poorly contrast-enhancing, involving the cerebral cortex and subcortical white matter, with a predilection for the temporal and occipital lobes. In NLE, lesions are predominantly in the white matter, often with cavitation. In eosinophilic meningoencephalitis, there may be diffuse meningeal enhancement. MRI may also show signs of increased intracranial pressure, such as cerebral edema, herniation, or hydrocephalus. Computed tomography (CT) is less sensitive but may show hypodense lesions or mass effect. Ultrasonography is not useful for CNS imaging. Advanced imaging techniques, such as diffusion-weighted imaging (DWI) and magnetic resonance spectroscopy, may provide additional information but are not routinely used in veterinary practice.

CSF cytology is a key diagnostic tool. In MUO, CSF typically shows a mixed mononuclear pleocytosis, with a predominance of small and large lymphocytes, macrophages, and occasionally plasma cells. In eosinophilic meningoencephalitis, eosinophils are prominent. The total nucleated cell count is usually elevated (often >10 cells/µL, sometimes >100 cells/µL). Protein concentration is elevated. Histopathology, obtained via biopsy or at necropsy, reveals perivascular infiltration of mononuclear cells (lymphocytes, macrophages, plasma cells) in the meninges and parenchyma. In GME, there are characteristic granulomatous lesions with epithelioid macrophages and multinucleated giant cells. In NME, there is severe necrosis of the neuropil with minimal inflammation. In NLE, there is leukoencephalomalacia with cavitation. Special stains, such as immunohistochemistry for CD3 (T-cells) and CD20 (B-cells), can help characterize the inflammatory infiltrate. Stains for infectious agents (e.g., Gram, Giemsa, PAS) are typically negative.

Treatment of MUO is aimed at suppressing the aberrant immune response. The mainstay of therapy is immunosuppressive doses of corticosteroids, such as prednisone or prednisolone, at 1-2 mg/kg/day PO, divided q12h, for 2-4 weeks, then gradually tapered over several months. In severe cases, a higher dose (e.g., 2-4 mg/kg/day) may be used. For rapid effect, dexamethasone (0.1-0.2 mg/kg IV) may be given initially. Adjunctive immunomodulatory drugs are often used to allow for lower corticosteroid doses and to improve efficacy. Commonly used agents include cytosine arabinoside (cytarabine) at 50-100 mg/m² SC or IV, given as a continuous infusion or divided into two doses, every 3-4 weeks; leflunomide at 2-4 mg/kg PO q24h; mycophenolate mofetil at 20-30 mg/kg PO q12h; and cyclosporine at 5-10 mg/kg PO q12h. These drugs are often used in combination with corticosteroids. In cases with increased intracranial pressure, mannitol (0.5-1 g/kg IV over 20 minutes) or hypertonic saline may be administered. Anticonvulsant therapy (e.g., levetiracetam 20 mg/kg PO q8h, phenobarbital 2.5 mg/kg PO q12h) is indicated for seizures. Supportive care includes fluid therapy, nutritional support, and nursing care for recumbent patients. In refractory cases, radiation therapy has been used for focal GME lesions, but it is not widely available. Surgical resection may be considered for solitary mass lesions, but it is rarely performed.

The prognosis for MUO is variable and depends on the form, severity, and response to therapy. With aggressive immunosuppressive treatment, many dogs achieve remission, with a median survival time of 1-2 years. However, some dogs do not respond to therapy and may die or be euthanized within weeks to months. Factors associated with a poorer prognosis include severe neurological deficits, brainstem involvement, increased intracranial pressure, and lack of response to corticosteroids. The presence of seizures may also be a negative prognostic indicator. In one study, dogs with GME had a median survival of 1.5 years, while those with NME had a median survival of 0.5 years. Eosinophilic meningoencephalitis may have a better prognosis. Relapses are common, and long-term immunosuppression is often required. Some dogs may have a good quality of life for several years, but the disease is ultimately progressive in many cases.

Follow-up is essential for monitoring response to therapy and adjusting drug dosages. Initially, re-evaluation should be performed every 2-4 weeks, including neurological examination and assessment of clinical signs. Serial CSF analysis may be performed to monitor inflammation, but it is not always necessary if the dog is improving. Blood work, including CBC and serum biochemistry, should be monitored regularly, especially when using immunosuppressive drugs, to detect adverse effects such as bone marrow suppression, hepatotoxicity, or renal toxicity. Drug levels may be monitored for certain drugs (e.g., cyclosporine). Imaging (MRI) may be repeated if there is a lack of response or worsening of signs. The corticosteroid dose should be tapered gradually over several months, with close observation for relapse. If relapse occurs, the dose may be increased or an additional immunomodulatory drug may be added. Long-term management may require lifelong therapy, and owners should be educated about the signs of relapse and the importance of compliance.

Pearls: 1) Always perform MRI before CSF collection to avoid iatrogenic changes and to identify any mass lesions that may increase the risk of herniation. 2) In any young to middle-aged small-breed dog with seizures and multifocal neurological signs, MUO should be high on the differential list. 3) CSF analysis is crucial; a mononuclear pleocytosis with elevated protein is highly supportive. 4) Start immunosuppressive therapy promptly if MUO is suspected, as early treatment improves outcomes. 5) Consider adding an adjunctive immunomodulatory drug (e.g., cytarabine) to reduce corticosteroid side effects and improve efficacy. Pitfalls: 1) Do not delay treatment while waiting for infectious disease test results, as this can be fatal. 2) Avoid using non-steroidal anti-inflammatory drugs (NSAIDs) in conjunction with corticosteroids, as this increases the risk of gastrointestinal ulceration. 3) Do not taper corticosteroids too quickly, as this often leads to relapse. 4) Be cautious with CSF collection in dogs with increased intracranial pressure; it can precipitate herniation. 5) Do not assume that a negative infectious disease test completely rules out infection; some organisms may be difficult to detect.

Based on Plumb's Veterinary Drug Handbook, the following protocols are commonly used: 1) Prednisone/prednisolone: 1-2 mg/kg PO q12h for 2-4 weeks, then taper by 25% every 2-4 weeks to a maintenance dose of 0.5 mg/kg PO q48h or lower. For severe cases, initial dose may be 2-4 mg/kg/day. 2) Dexamethasone: 0.1-0.2 mg/kg IV or SC once, then switch to oral prednisone. 3) Cytarabine (cytosine arabinoside): 50-100 mg/m² SC or IV, given as a 2-hour continuous infusion or divided into two doses, every 3-4 weeks. It is often used in combination with prednisone. 4) Leflunomide: 2-4 mg/kg PO q24h. It may take 4-6 weeks to achieve full effect. 5) Mycophenolate mofetil: 20-30 mg/kg PO q12h. 6) Cyclosporine: 5-10 mg/kg PO q12h. Monitor trough levels if possible. 7) For seizures: levetiracetam 20 mg/kg PO q8h; phenobarbital 2.5 mg/kg PO q12h, with therapeutic monitoring (target 25-40 µg/mL). 8) For increased intracranial pressure: mannitol 0.5-1 g/kg IV over 20 minutes, repeated as needed; or hypertonic saline (3%) at 1-2 mL/kg IV over 15 minutes. 9) Gastroprotectants: omeprazole 1 mg/kg PO q12h or famotidine 0.5 mg/kg PO q12h, especially when using corticosteroids. 10) Always adjust doses in patients with hepatic or renal impairment, and monitor for drug interactions.

Several studies have evaluated the treatment and prognosis of MUO. A landmark study by Munana and Luttgen (1998) reported that dogs with GME treated with corticosteroids alone had a median survival of 1.5 years, while those treated with radiation therapy had a median survival of 2.5 years. A more recent study by Lowrie et al. (2013) compared prednisone alone versus prednisone plus cytarabine and found no significant difference in survival, but the combination group had a lower incidence of adverse effects. Another study by Coates et al. (2007) evaluated the use of leflunomide in dogs with MUO and reported a median survival of 1.5 years. A consensus statement from the American College of Veterinary Internal Medicine (ACVIM) on the diagnosis and treatment of inflammatory CNS diseases was published in 2016, recommending immunosuppressive doses of corticosteroids as first-line therapy, with adjunctive immunomodulatory drugs for refractory cases. The use of MRI and CSF analysis for diagnosis is well-established. Overall, the evidence supports the use of immunosuppressive therapy, but the optimal protocol remains to be determined. More research is needed to identify biomarkers for prognosis and to develop targeted therapies.